Concept Life Sciences providing ‘fully integrated offering’ in the early development space
The new clinical and niche commercial facility will add current good manufacturing practice (cGMP) active pharmaceutical ingredient (API) synthesis from gram-scale to multi-kilo capability, said Dr. Paul Doyle, chief scientific officer.
The facility and offering complements the company’s other sites, which provide analytical, stability, material science, and formulation services.
“Ultimately this results in a fully integrated offering in the early development space to support pharmaceutical and biotechnology companies throughout the development and manufacture of active pharmaceutical ingredients,” Doyle told us.
The company’s business has been driven by customer demand in what Doyle described as a growing marketplace – some forecasts suggest the API market will be worth more than $274.9bn by 2026, he said.
“Concept Life Sciences is seeing the highest demand from our customers when they are transitioning from late lead optimization through to preclinical and clinical development,” Doyle added.
“Adding cGMP API capabilities allows a seamless transition from gram-scale chemistry through to non-GMP and GMP production,” he said, “thus allowing us to support customers moving into these different phases of development.”
